LRRC27: A Potential Drug Target and Biomarker for Various Diseases

Target Name: LRRC27

NCBI ID: G80313

LRRC27

LRRC27: A Potential Drug Target and Biomarker for Various Diseases

LRRC27 (Long non-coding RNA-rich chromosome 27) is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. LRRC27 is a non-coding RNA gene that is located on chromosome 27, making it the most prominent gene on the chromosome.

The LRRC27 gene is expressed in almost all human tissues and has been implicated in various biological processes. It is a key regulator of cell adhesion and has been linked to the development and progression of various diseases. LRRC27 has also been shown to play a role in cancer progression and has been used as a potential therapeutic target in cancer treatments.

One of the key features of LRRC27 is its ability to interact with various signaling pathways. LRRC27 has been shown to interact with various signaling pathways, including TGF-β, NF-kappa-B, and PI3K/AKT. These signaling pathways are involved in various cellular processes, including cell growth, differentiation, and inflammation.

LRRC27 has also been shown to play a role in the regulation of gene expression. It has been shown to regulate the expression of various genes, including PDGF-尾, NF-kappa-B, and TGF-β. These genes are involved in various cellular processes, including cell growth, differentiation, and inflammation.

In addition to its role in cell signaling pathways, LRRC27 has also been shown to play a role in the regulation of cellular processes that are important for maintaining tissue homeostasis. It has been shown to regulate the migration and invasion of cells, as well as the production of extracellular matrix (ECM) components.

LRRC27 has also been implicated in the development and progression of various diseases. For example, LRRC27 has been shown to be overexpressed in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This overexpression has been shown to contribute to the development and progression of these diseases.

In addition to its potential clinical applications, LRRC27 is also a potential biomarker for various diseases. For example, LRRC27 has been shown to be elevated in the blood of patients with various cancers, including breast, lung, and colorectal cancers. This increase in LRRC27 has been shown to be associated with poor prognosis in these patients.

LRRC27 has also been shown to be regulated by various factors, including DNA methylation and histone modifications. These factors can affect the stability and expression of LRRC27, and may play a role in its regulation of cellular processes.

In conclusion, LRRC27 is a non-coding RNA gene that has been shown to play a role in various biological processes. Its ability to interact with various signaling pathways and regulate gene expression makes it a potential drug target and biomarker for various diseases. Further research is needed to fully understand the role of LRRC27 in these diseases and to develop effective therapies based on its properties.

Protein Name: Leucine Rich Repeat Containing 27

The "LRRC27 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRRC27 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets